In the field of immunology, research on T cell receptors (TCR) has always been a hotspot. TCRs activate T cells by recognizing and binding to peptide-MHC complexes on the surface of antigen-presenting cells. With the advancement of biotechnology, especially the popularization of high-throughput sequencing technologies, researchers can obtain a large amount of TCR sequence data, which is crucial for understanding the diversity and pathological mechanisms of the immune system[1].

However, existing studies often rely on traditional biostatistical methods or high-demand deep learning techniques to analyze TCR data. These methods often fall short when handling complex biological data. For example, existing methods struggle to accurately predict the binding affinity between TCRs and specific peptide-MHC complexes, limiting their application in precision medicine and personalized immunotherapy[2].

To overcome these limitations, this study employs more advanced machine learning algorithms, which have shown their superiority in other bioinformatics fields. By integrating various types of data and algorithms, it is possible to enhance the accuracy and efficiency of TCR analysis, thus better advancing research outcomes and clinical applications in immunology.

In this study, advanced machine learning methods were used to analyze TCR sequence data. By comparing the performance of traditional methods and new algorithms, the potential applications of these new technologies in TCR research were explored. The results not only demonstrate the advantages of new algorithms in processing TCR data but also provide a new perspective on understanding the diversity of TCRs[3].

With the further development of computing and biotechnologies, TCR research combined with machine learning is expected to become more precise and efficient[4]. This will not only deepen our understanding of how the immune system recognizes and responds to pathogens but also promises to advance personalized medical and precision immunotherapy strategies, providing more personalized and effective treatment options for patients.

[1] K. Shah, A. Al-Haidari, J. Sun, and J. U. Kazi, ‘T cell receptor (TCR) signaling in health and disease’, *Signal Transduct. Target. Ther.*, vol. 6, no. 1, p. 412, Dec. 2021, doi: 10.1038/s41392-021-00823-w.

[2] C. Szeto, C. A. Lobos, A. T. Nguyen, and S. Gras, ‘TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers’, *Int. J. Mol. Sci.*, vol. 22, no. 1, p. 68, Dec. 2020, doi: 10.3390/ijms22010068.

[3] Z. A. Rollins, M. B. Curtis, R. Faller, and S. C. George, ‘Automated protein-protein structure prediction of the T cell receptor-peptide major histocompatibility complex’. Jun. 01, 2022. doi: 10.1101/2022.06.01.494331.

[4] A.-L. Schaap-Johansen, M. Vujović, A. Borch, S. R. Hadrup, and P. Marcatili, ‘T Cell Epitope Prediction and Its Application to Immunotherapy’, *Front. Immunol.*, vol. 12, p. 712488, Sep. 2021, doi: 10.3389/fimmu.2021.712488.